Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.54 |
| ▸ | ADH1B | P00325 | 1/20 | 0.48 |
| ▸ | ADH1C | P00326 | 1/20 | 0.48 |
| ▸ | ADH1A | P07327 | 1/20 | 0.48 |
| ▸ | ADH4 | P08319 | 1/20 | 0.48 |
| ▸ | ADH7 | P40394 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18966933 | 1.00 | SIGMAR1 (0.54) | SIGMAR1ADH1BADH1CADH1AADH4 | |
| SCHEMBL1678659 | 1.00 | SIGMAR1 (0.54) | SIGMAR1ADH1BADH1CADH1AADH4 | |
| SCHEMBL338123 | 1.00 | — | — | |
| SCHEMBL19143227 | 1.00 | SIGMAR1 (0.54) | SIGMAR1ADH1BADH1CADH1AADH4 | |
| SCHEMBL18994846 | 1.00 | SIGMAR1 (0.54) | SIGMAR1ADH1BADH1CADH1AADH4 | |
| SCHEMBL23637574 | 1.00 | SIGMAR1 (0.54) | SIGMAR1ADH1BADH1CADH1AADH4 | |
| SCHEMBL22618111 | 1.00 | SIGMAR1 (0.54) | SIGMAR1ADH1BADH1CADH1AADH4 | |
| SCHEMBL20746876 | 1.00 | SIGMAR1 (0.54) | SIGMAR1ADH1BADH1CADH1AADH4 | |
| SCHEMBL21106601 | 1.00 | SIGMAR1 (0.54) | SIGMAR1ADH1BADH1CADH1AADH4 | |
| Hydrochloric Acid SCHEMBL2197235 | 0.97 | SIGMAR1 (0.52) | SIGMAR1ADH1BADH1CADH1AADH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230305396-A1 | Euv Photoresist With Low-Activation-Energy Ligands Or High-Developer-Solubility Ligands | TAIWAN SEMICONDUCTOR MANUFACTURING CO., LTD. (TW) | 2023-09-28 | — | — | US | disclosed |
| WO-2023170715-A1 | DUAL LSD1/HDAC INHIBITORS | Jubilant Epicore LLC (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023171694-A1 | CORE-SHELL TYPE HETEROGENEOUS CATALYST AND MANUFACTURING METHOD FOR OPTICALLY ACTIVE COMPOUND EMPLOYING SAME | 国立大学法人東京大学 | 2023-09-14 | — | — | WO | disclosed |
| US-20220380520-A1 | STRONG BINDING METAL-CHELATING RESINS USING MACROCYCLE MOLECULES | SACHEM, INC. | 2022-12-01 | — | — | US | disclosed |
| US-9822356-B2 | Fluidic devices and systems for sample preparation or autonomous analysis | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2017-11-21 | — | — | US | disclosed |
| US-7923573-B2 | Benzene compound having 2 or more substituents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-12 | — | — | US | disclosed |
| US-20080255111-A1 | Tissue Factor Production Inhibitor | SANKYO COMPANY LIMITED (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-01-03 | — | — | US | disclosed |
| EP-1806332-A1 | BENZENE COMPOUND HAVING 2 OR MORE SUBSTITUENTS | Daiichi Sankyo Company, Limited (JP) | 2007-07-11 | — | — | EP | disclosed |
| EP-1764075-A1 | TISSUE FACTOR PRODUCTION INHIBITOR | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255111-A1 | Tissue Factor Production Inhibitor | PTAFR, PLAT, TFPI | SIGMAR1 4028/4885ADH1B 2487/4885ADH1C 4567/4885 |
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | NR1H2, NR1H3, NCOR2 | SIGMAR1 706/4885ADH1B 998/4885ADH1C 3082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.